



INSTITUTE FOR ANIMAL HEALTH
Director: Professor Martin W. Shirley, PhD
PIRBRIGHT LABORATORY
Ash Road,
Pirbright,
Surrey,
GU24 0NF
Intn Tel: 00 44 1483 232441
Tel: 01483 232441 Fax: 01483 232621

FMD Vaccine Matching Strain Differentiation Report

Lab Reference WRL Batch Number: WRLFMD/2009/00032

Sender Details:

Date Received:

2nd July 2009

Country of Origin:

Palestinian Autonomous Territories

Date Reported:

13th November 2009

Results Approved

Official Stamp:

Date:

13/11/09

To help us improve the quality of our service, please send any suggestions or requests to the Reference Laboratory by fax (+44 (0) 1483 232621 or email: elizabeth.wilson@bbsrc.ac.uk)

Report no:	VNT							LPBE			
Vaccine:	A22 Irq	A Tur06	A Sau 41/91	A Ind 17/82	A Irn87	A Irn99	A May 97		A Irn 87	A22 Irq 24/64	
Field Isolate:											
A PAT 1/2009	Mean	0.09	0.24	0.08	0.26	0.08	<0.09	0.08	Mean	0.06	DNT
A PAT 6/2009	Mean	0.19	0.75	0.36	0.43	0.08	0.09	0.13	Mean	0.24	0.42

Interpretation of Results

In the case of Virus Neutralisation Test (VNT):

$r_1 = \geq 0.3$. Suggests that there is a close relationship between field isolate and vaccine strain. A potent vaccine containing the vaccine strain is likely to confer protection.

$r_1 = < 0.3$. Suggests that the field isolate is so different from the vaccine strain that the vaccine is unlikely to protect

In the case of Liquid Phase Blocking Elisa (LPBE):

$r_1 = 0.4-1.0$. Suggests that there is a close relationship between field isolate and vaccine strain. A potent vaccine containing the vaccine strain is likely to confer protection.

$r_1 = 0.2-0.39$, Suggests that the field isolate is antigenically related to the vaccine strain. The vaccine strain might be suitable for use if no closer match can be found provided that a potent vaccine is used and animals are preferably immunised more than once.

$r_1 = < 0.2$. Suggests that the field isolate is so different from the vaccine strain that the vaccine is unlikely to protect.